Luciano Adorini

5PUBLICATIONS
14CO-AUTHORS
Medical mycologyPredictive and prognostic markersMolecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 27, 2025
Farnesoid X Receptor Agonist INT-787 Inhibits Hepatic Mitochondrial Dysfunction in a Diet-Induced ob/ob Mouse Model of MASH.

Laura Giuseppina Di Pasqua, Giuseppina Palladini, Anna Cleta Croce

|Jun 26, 2025
Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function.

Caitriona E Curley, Natalia K Lajczak-McGinley, Luciano Adorini

|Apr 25, 2024
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.

Luciano Adorini, Kristoffer Rigbolt, Michael Feigh

|Jul 09, 2022
Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism.

Justine Gillard, Corinne Picalausa, Christoph Ullmer

|Jan 25, 2019
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

S Di Matteo, L Nevi, D Costantini

Pageof 1

Frequent Collaborators

1 joint publications

S Di Matteo

1 joint publications

L Nevi

1 joint publications

D Overi

1 joint publications

G Grazi